Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois. Gastroenterol Hepatol (N Y) (2015) 2.20

Hepatitis C. Lancet (2015) 1.95

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. Am Health Drug Benefits (2015) 1.37

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois. Gastroenterol Hepatol (N Y) (2014) 1.27

In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother (2014) 1.23

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother (2014) 1.20

Cost-effectiveness of screening for hepatitis C in Canada. CMAJ (2015) 1.16

KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15

Treating hepatitis C - what's new? Aust Prescr (2015) 1.12

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology (2016) 1.10

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology (2015) 1.09

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother (2014) 1.05

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clin Pharmacokinet (2016) 0.99

Advances in hepatitis C therapy: What is the current state - what come's next? World J Hepatol (2016) 0.98

Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol (2015) 0.97

Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med (2015) 0.97

APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96

Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology (2016) 0.93

Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother (2015) 0.90

Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol (2016) 0.90

Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol (2015) 0.89

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses (2015) 0.89

Update on hepatitis C: Direct-acting antivirals. World J Hepatol (2015) 0.88

New treatment strategies for hepatitis C infection. World J Hepatol (2015) 0.88

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. AAPS J (2015) 0.87

New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2015) 0.86

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS One (2015) 0.86

Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol (2015) 0.86

Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open (2016) 0.85

SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85

Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clin Pharmacokinet (2016) 0.85

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. AIDS Patient Care STDS (2015) 0.83

Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C. Aust Prescr (2016) 0.83

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir. Antimicrob Agents Chemother (2015) 0.83

CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Can J Infect Dis Med Microbiol (2015) 0.83

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther (2015) 0.83

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol (2016) 0.82

Hepatitis C: Treatment triumphs. Nature (2014) 0.82

Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother (2015) 0.82

Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World J Hepatol (2015) 0.81

Recent advances in management of the HIV/HCV coinfected patient. Future Virol (2016) 0.81

Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. PLoS One (2016) 0.81

New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res (2014) 0.80

Hepatitis C Infection in the Elderly. Dig Dis Sci (2015) 0.80

Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol (2015) 0.80

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80

Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol (2016) 0.80

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med (2017) 0.79

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver Int (2015) 0.79

Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada. Can J Gastroenterol Hepatol (2015) 0.79

Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase Allosterically Block the Transition from Initiation to Elongation. J Biol Chem (2016) 0.79

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. CMAJ Open (2017) 0.78

Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis (2016) 0.78

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrob Agents Chemother (2015) 0.78

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther (2015) 0.78

Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol (2015) 0.78

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol (2016) 0.78

Hepatitis C: Treatment of difficult to treat patients. World J Hepatol (2015) 0.78

Retrospective analysis of hepatitis C infected patients treated through an integrated care model. World J Gastroenterol (2016) 0.77

Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer? J Clin Gastroenterol (2016) 0.77

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (Baltimore) (2016) 0.77

Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation. Adv Chronic Kidney Dis (2015) 0.77

Labour productivity losses caused by premature death associated with hepatitis C in Spain. Eur J Gastroenterol Hepatol (2015) 0.77

The New Era of Interferon-Free Treatment of Chronic Hepatitis C. Viszeralmedizin (2015) 0.77

Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol (2015) 0.77

Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. PLoS Comput Biol (2015) 0.77

Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol (2016) 0.77

Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant (2015) 0.76

Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol (2015) 0.76

Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med (2016) 0.76

Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir. Antimicrob Agents Chemother (2015) 0.76

Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine. Antimicrob Agents Chemother (2016) 0.75

PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics (2015) 0.75

HCV cure for everyone or which challenges remain? J Virus Erad (2015) 0.75

Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications. World J Hepatol (2015) 0.75

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PLoS One (2015) 0.75

Ribavirin: Past, present and future. World J Hepatol (2016) 0.75

Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. World J Hepatol (2016) 0.75

Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol (2016) 0.75

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Hosp Pharm (2015) 0.75

The dollars and sense of chronic hepatitis C infection management. Can J Infect Dis Med Microbiol (2015) 0.75

Viral hepatitis: new hepatitis C therapies-a medical pick and mix. Nat Rev Gastroenterol Hepatol (2014) 0.75

Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. Sci Rep (2016) 0.75

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC Infect Dis (2015) 0.75

Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2015) 0.75

Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol (2016) 0.75

Management of HCV-Associated Liver Cirrhosis. Visc Med (2016) 0.75

HCV Council - critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int (2015) 0.75

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol (2016) 0.75

A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res (2016) 0.75

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications. Infect Dis Ther (2015) 0.75

Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Non-Macrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease. Antimicrob Agents Chemother (2016) 0.75

Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS One (2016) 0.75

Hepatitis C virus infection: accessing drug treatment. CMAJ (2015) 0.75

Anti-hepatitis C virus drugs and kidney. World J Hepatol (2016) 0.75

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31

Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21

Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49

Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet (2010) 6.52

Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14

Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89

Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl (2012) 4.65

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72

Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet (2013) 3.40

Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35

Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13

An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97

Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91

Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77

IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology (2015) 2.76

Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis (2010) 2.71

Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology (2002) 2.68

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis (2003) 2.68

Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58

Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology (2010) 2.53

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50

Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43

Needlestick injuries among surgeons in training. N Engl J Med (2007) 2.37